Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized open-label study of SHP607 to prevent chronic lung disease in extremely preterm infants
MOH_2019-09-02_007381Phase 3Completed
- Sponsor
- Premacure
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by Premacure. Primary endpoint: Clinical efficacy and safety through 12 months corrected age. Started Aug 2019; status: completed.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on MOH_2019-09-02_007381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-02_007381.